Costa DB - Search Results

1

Cheng MP, Marty FM, Costa DB, Awad MM. Cheng MP, et al. Among authors: costa db. J Thorac Oncol. 2018 Nov;13(11):e237. doi: 10.1016/j.jtho.2018.09.015. J Thorac Oncol. 2018. PMID: 30368420 Free article. No abstract available.

2

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Costa DB, et al. Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455. Clin Cancer Res. 2008. PMID: 18981003 Free PMC article.

3

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Nguyen KS, Kobayashi S, Costa DB. Nguyen KS, et al. Among authors: costa db. Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. Clin Lung Cancer. 2009. PMID: 19632948 Free PMC article. Review.

4

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Yeo WL, et al. Among authors: costa db. J Thorac Oncol. 2010 Jul;5(7):1048-53. doi: 10.1097/JTO.0b013e3181dd1386. J Thorac Oncol. 2010. PMID: 20512075 Free PMC article.

5

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Heon S, et al. Among authors: costa db. Clin Cancer Res. 2010 Dec 1;16(23):5873-82. doi: 10.1158/1078-0432.CCR-10-1588. Epub 2010 Oct 28. Clin Cancer Res. 2010. PMID: 21030498 Free PMC article.

6

KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.

Ortiz TM, Cohen DW, Kent MS, Jänne PA, Costa DB. Ortiz TM, et al. Among authors: costa db. J Thorac Oncol. 2011 Jan;6(1):220-2. doi: 10.1097/JTO.0b013e3181f8a164. J Thorac Oncol. 2011. PMID: 21178719 Free PMC article. No abstract available.

7

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

Klempner SJ, Cohen DW, Costa DB. Klempner SJ, et al. Among authors: costa db. J Thorac Oncol. 2011 Aug;6(8):1439-40. doi: 10.1097/JTO.0b013e3182217c01. J Thorac Oncol. 2011. PMID: 21847065 Free PMC article. No abstract available.

8

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

Costa DB, Kobayashi S. Costa DB, et al. J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab. J Thorac Oncol. 2012. PMID: 22334013 Free article. No abstract available.

9

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Yasuda H, et al. Among authors: costa db. J Thorac Oncol. 2012 Jul;7(7):1086-90. doi: 10.1097/JTO.0b013e3182570919. J Thorac Oncol. 2012. PMID: 22617245 Free PMC article.

10

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Heon S, et al. Among authors: costa db. Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25. Clin Cancer Res. 2012. PMID: 22733536 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page